We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Novel Flowable Hemostatic Agent ActiClot: Efficacy and Safety Assessment in Rat and Porcine Models.
- Authors
Kim, Hee-Jung; Lee, Su-Kyoung; Ko, Yun-Jeh; Jeon, Soo-Hyeon; Kim, Eun-Jin; Kwon, Oh-Hyeong; Cho, Yang-Hyun
- Abstract
Background/Objectives: This study evaluated the hemostatic performance and safety of ActiClot (ATC), a new flowable hemostatic agent, through in vivo tests. Methods: ATC was compared with the commercially available FLOSEAL®. ATC consists of carboxymethyl starch, thrombin, and sorbitol powders in Syringe I, and a calcium chloride solution in Syringe II. In vivo evaluation used rat liver bleeding and porcine heart bleeding models. Safety was assessed using a rat subcutaneous implantation model. Results: ATC significantly reduced hemostasis time (70.00 ± 7.35 s) compared to gauze control (240.63 ± 32.31 s) in the rat liver model, showing a 70% reduction. There was no significant difference between ATC and FLOSEAL® (58.75 ± 13.42 s). In the porcine heart model, both agents achieved 100% hemostasis within 3 min, with no significant difference in success rates within 2 min (ATC 87.5%, FLOSEAL® 75%). The gauze control group failed in all tests. The rat subcutaneous implantation model showed no visual ATC observation after 48 h, indicating biocompatibility, with no inflammation observed. Conclusions: ATC demonstrated effective hemostatic performance similar to FLOSEAL® in two in vivo models, with faster hemostasis in the rat liver model. It also showed excellent safety and biocompatibility, indicating its potential for surgical and emergency bleeding control.
- Subjects
LABORATORY rats; SURGICAL emergencies; CALCIUM chloride; IN vivo studies; HEMOSTASIS
- Publication
Journal of Clinical Medicine, 2024, Vol 13, Issue 16, p4770
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm13164770